NurExone Biologic (J90) Financial Statements

4 Followers

NurExone Biologic Financial Overview

NurExone Biologic's market cap is currently €29.63M. The company's EPS TTM is €-0.08; its P/E ratio is -6.35; NurExone Biologic is scheduled to report earnings on June 3, 2026, and the estimated EPS forecast is €-0.02. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Dec 22	Mar 22
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Income	$ -6.32M	$ -5.01M	$ -3.66M	$ -7.62M	$ -1.68M
EBITDA	$ -6.17M	$ -4.94M	$ -3.60M	$ -8.12M	$ -1.68M
Net Income	$ -6.38M	$ -5.04M	$ -3.64M	$ -8.17M	$ -1.62M
Balance Sheet
Cash & Short-Term Investments	$ 2.14M	$ 700.00K	$ 541.00K	$ 2.46M	$ 2.21M
Total Assets	$ 4.08M	$ 2.44M	$ 2.17M	$ 2.79M	$ 2.81M
Total Debt	$ 108.00K	$ 33.00K	$ 20.00K	$ 44.00K	$ 1.03M
Net Debt	$ -2.03M	$ -667.00K	$ -521.00K	$ -2.42M	$ -1.18M
Total Liabilities	$ 1.32M	$ 680.00K	$ 1.98M	$ 698.00K	$ 1.64M
Stockholders' Equity	$ 2.76M	$ 1.76M	$ 189.00K	$ 2.10M	$ 1.17M
Cash Flow
Free Cash Flow	$ -4.57M	$ -5.54M	$ -3.06M	$ -3.90M	$ -1.21M
Operating Cash Flow	$ -4.51M	$ -4.89M	$ -2.94M	$ -3.85M	$ -1.21M
Investing Cash Flow	$ -55.00K	$ -658.00K	$ -97.00K	$ -89.00K	$ 0.00
Financing Cash Flow	$ 5.83M	$ 5.88M	$ 1.13M	$ 4.29M	$ 3.40M

Currency in USD

NurExone Biologic Earnings and Revenue History

Income Statement >

NurExone Biologic Debt to Assets

Balance Sheet >

NurExone Biologic Cash Flow

Cash Flow >

NurExone Biologic Forecast EPS vs Actual EPS

Earnings >